biostudies-literatureUnknown55(2)Macaluso FS<h4>Background</h4>Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy.<h4>Aims</h4>To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).<h4>Results</h4>1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reporteDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver154-159https://www.ebi.ac.uk/biostudies/studies/S-EPMC9420701biostudies-literatureReduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.PMC9420701Furfaro FSaibeni SMilla MRizzo GO'Sed NPFelice CSpagnuolo RPaba SRiguccio GCasa ATodeschini ACorreale CConforti FSMulinacci GBodini GDesideri FBezzio CFacciotti FDe Bona MRadice SRibaldone DGMacaluso FSFiorino GCaprioli FMannino MOrlando AItalian Group for the study of Inflammatory Bowel Disease (IG-IBD)Doldo PVigano CScardino GVernero MFantini MCPrincipi MAmato ACastiglione FCalabrese GRizzuto GContaldo ANardone OMRenna SDemarzo MGAscolani MOlmo OComberlato MDragoni GfalseReduced humoral response to two doses of COVID-19 vaccine in patients with inflammatory bowel disease: Data from ESCAPE-IBD, an IG-IBD study.<h4>Background</h4>Patients on immunosuppressive drugs have been excluded from COVID-19 vaccines trials, creating concerns regarding their efficacy.<h4>Aims</h4>To explore the humoral response to COVID-19 vaccines in patients with inflammatory bowel disease (IBD) METHODS: Effectiveness and Safety of COVID-19 Vaccine in Patients with Inflammatory Bowel Disease (IBD) Treated with Immunomodulatory or Biological Drugs (ESCAPE-IBD) is a prospective, multicentre study promoted by the Italian Group for the study of Inflammatory Bowel Disease. We present data on serological response eight weeks after the second dose of COVID-19 vaccination in IBD patients and healthy controls (HCs).<h4>Results</h4>1076 patients with IBD and 1126 HCs were analyzed. Seropositivity for anti-SARS-CoV-2 IgG was reporte2023-01-01T00:00:00Z2023 Feb2025-04-18T18:41:53.781Z2025-02-19T03:29:03.069ZS-EPMC94207013612722810.1016/j.dld.2022.08.027